Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2003

Content (13 Articles)

Expedition Inspiration Fund for Breast Cancer Research Meeting 2003

Harry Bartelink, Christopher Benz, Don Cleveland, Ronald Dorn, Julie Gralow, William J. Gradishar, Kathleen Grant, Ruth Heimann, Samuel Hellman, Clifford Hudis, Robert Kerbel, Marc Lippman, John Lung, Mitchell C. Posner, Patricia Steeg, Robert Vestal, Ralph R. Weichselbaum, Bruce Zetter

Genetic Polymorphisms of Platelet Adhesive Molecules: Association with Breast Cancer Risk and Clinical Presentation

Francisco Ayala, Javier Corral, Rocío González-Conejero, Ignacio Sánchez, José María Moraleda, Vicente Vicente

H-ras Dependent Estrogenic Effects of Epidermal Growth Factor in the Estrogen-Independent Breast Cancer Cell Line MDA-MB-231

Oliver Treeck, Angela Weber, Michaela Boester, Simone Porz, Nicola Frey, Klaus Diedrich, Olaf Ortmann

Overexpression of Cyclin A Overrides the Effect of p53 Alterations in Breast Cancer Patients with Long Follow-up Time

Ida RK Bukholm, Anne Husdal, Jahn M. Nesland, Anita Langerød, Geir Bukholm

HER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile Changing

Gian Paolo Dagrada, Alessandra Mezzelani, Loredana Alasio, Mario Ruggeri, Roberta Romanò, Marco A. Pierotti, Silvana Pilotti

The Expression of DCC Protein in Female Breast Cancer

Rumelia Koren, Yoram Dekel, Evgeny Sherman, Yona Weissman, Zeev Dreznik, Baruch Klein, Rivka Gal

Inhibition of Invasion and Metastasis by Glypican-3 in a Syngeneic Breast Cancer Model

M.G. Peters, E. Farías, L. Colombo, J. Filmus, L. Puricelli, E. Bal de Kier Joffé

Erratum, Axilla Surgery Severely Affects Quality of Life: Results of a 5-year Prospective Study in Breast Cancer Patients

Jutta Engel, Jacqueline Kerr, Anne Schlesinger-Raab, Hansjörg Sauer, Dieter Hölzel

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine